Atlas Trials

Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant

Clinical trial NCT00044733 · COMPLETED

Trial details

NCT number
NCT00044733
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Acute Myelogenous Leukemia
Start date
2000-03-01
Enrollment
38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.